Betalain Composition With High Active Ratio and Stable Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current red beet preparations suffer from low betalain concentration, hygroscopicity, clumping, and instability, limiting their effectiveness in treating conditions like osteoarthritis, acne, and allergic reactions, and they often contain high sugar content and caffeine, leading to undesirable side effects.
Innovation Solution
Development of betalain-containing compositions with a concentration of at least 2 wt% betalains, a betalain to sugar ratio of at least 1.0, and stable formulations that dissolve well in water, reducing sugar content and avoiding caffeine, administered orally to treat conditions such as osteoarthritis, acne, and allergic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If red beet preparations are used to treat conditions like osteoarthritis and allergic reactions, then therapeutic effectiveness is improved, but the preparations suffer from low betalain concentration and high sugar content leading to reduced efficacy and undesirable side effects
Solution Approach 1:
The patent extracts betalains from red beet sources and isolates them from other components, particularly sugar. The composition contains at least 2 wt% betalains with a betalain to sugar ratio of at least 1.0, achieved through extraction processes that separate the active betalain compounds from the high sugar content of whole red beet preparations.
Solution Approach 2:
The patent creates a composition with non-uniform distribution of components, concentrating betalains in specific formulations while controlling sugar content separately. The composition maintains at least 2 wt% betalains with controlled sugar content to achieve a betalain to sugar ratio of at least 1.0, ensuring high local concentration of therapeutic agents.
2Reliability
If conventional red beet preparations are used, then they provide betalain compounds, but they exhibit hygroscopicity and clumping that limit stability and effectiveness
Solution Approach 1:
The patent uses excipients and carriers as intermediary substances to prevent direct interaction between betalains and environmental moisture. These intermediary materials protect the betalain compounds from hygroscopicity and clumping, improving stability while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent creates a composite formulation combining betalains with other materials that reduce hygroscopicity and prevent clumping. The composition includes betalains at at least 2 wt% combined with excipients, carriers, or other materials that improve physical stability and prevent the hygroscopic and clumping properties of pure betalain extracts.
3Use of energy by moving object
If energy drinks with caffeine are consumed to provide energy and mental alertness, then stimulatory effects are achieved, but undesirable side effects occur including nervousness, irritability, and sleeplessness
Solution Approach 1:
The patent extracts and isolates betalain compounds from their natural sources, separating them from caffeine and other stimulatory substances. The composition provides energy and mental alertness benefits through betalains alone, without the harmful side effects of caffeine extraction.
Solution Approach 2:
The patent converts the natural stimulatory properties of betalains into a beneficial effect without the harmful aspects of caffeine. By using betalains as the active ingredient, the composition provides energy and mental alertness while avoiding caffeine-induced nervousness, irritability, and sleeplessness.
Data Source
AI summary
Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood.